Aaron Lisberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aaron Lisberg has a total of 193 co-authors. Here are the top co-authors by number of shared publications:
- Edward Brian Garon
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, USA
41 shared publications - Jonathan Wade Goldman
David Geffen School of Medicine at UCLA, Los Angeles, California
19 shared publications - Bin Liu
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
14 shared publications - Linh M. Tran
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
14 shared publications - Ramin Salehi-Rad
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
14 shared publications - Steven M. Dubinett
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, USA
14 shared publications
Latest Publications
- 17 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
Circulating TOX+ TIGIT+ CD57+ TEMRA CD8+ T cells are associated with efficacy of combined aPD-L1, aCTLA-4 and metronomic chemotherapy in advanced cervical cancer
To improve ICI efficacy in advanced CC, a promising strategy is to combine anti-PDL-1, anti-CTLA-4 and chemotherapy. The phase I/II MOVIE trial reported a clinical benefit rate of 53.1% of durvalumab, tremelimumab and metronomic oral vinorelbine in patients with pretreated metastatic CC. The objective of this study is to discover immune efficacy biomarkers of this combination. We analyzed 29 advanced CC patients from MOVIE multicentric prospective clinical trial (NCT03518606). We used high-dimensional mass cytometry (CyTOF) to explore the immune landscape in baseline peripheral blood mononuclear cells. We developed 3 immune panels of 40 antibodies (T cells, NK cells and myeloid cells) for the deep-phenotyping of PBMCs. Our bioinformatics workflow of CyTOF data included dimensionality reduction (opt-SNE, UMAP), automated clustering (PhenoGraph) and regression (CITRUS). The biomarker candidates were submitted to a model prediction composed of 11 machine-learning algorithms. In baseline blood samples, high-dimensional analyses consistently identified a population of TOX+TIGIT+CD57+ TEMRA (CD45RA+CCR7-) CD8+ T cells associated with improved clinical outcomes: clinical benefit (CB), progression-free survival (PFS) and overall survival (OS). This population was confirmed by manual gating and 11 machine-learning algorithms. After determining a cut-off at 0.73% of CD45+ cells, patients with an increased blood baseline frequency of TOX+TIGIT+CD57+ TEMRA (CD45RA+CCR7-) CD8+ T cells had an improved CBR (76% vs 25%, p=0.005), an improved PFS (HR=0.35, CI95, 0.13-0.95, p=0.013) and an improved OS (HR=0.19, CI95, 0.07-0.53, p=0.001). Multivariate analysis with classical CC prognostic factors confirmed the OS benefit of our biomarker (HR=0.15, CI95: 0.05-0.47, <0.001).
- 17 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
Circulating TOX+ TIGIT+ CD57+ TEMRA CD8+ T cells are associated with efficacy of combined aPD-L1, aCTLA-4 and metronomic chemotherapy in advanced cervical cancer
To improve ICI efficacy in advanced CC, a promising strategy is to combine anti-PDL-1, anti-CTLA-4 and chemotherapy. The phase I/II MOVIE trial reported a clinical benefit rate of 53.1% of durvalumab, tremelimumab and metronomic oral vinorelbine in patients with pretreated metastatic CC. The objective of this study is to discover immune efficacy biomarkers of this combination. We analyzed 29 advanced CC patients from MOVIE multicentric prospective clinical trial (NCT03518606). We used high-dimensional mass cytometry (CyTOF) to explore the immune landscape in baseline peripheral blood mononuclear cells. We developed 3 immune panels of 40 antibodies (T cells, NK cells and myeloid cells) for the deep-phenotyping of PBMCs. Our bioinformatics workflow of CyTOF data included dimensionality reduction (opt-SNE, UMAP), automated clustering (PhenoGraph) and regression (CITRUS). The biomarker candidates were submitted to a model prediction composed of 11 machine-learning algorithms. In baseline blood samples, high-dimensional analyses consistently identified a population of TOX+TIGIT+CD57+ TEMRA (CD45RA+CCR7-) CD8+ T cells associated with improved clinical outcomes: clinical benefit (CB), progression-free survival (PFS) and overall survival (OS). This population was confirmed by manual gating and 11 machine-learning algorithms. After determining a cut-off at 0.73% of CD45+ cells, patients with an increased blood baseline frequency of TOX+TIGIT+CD57+ TEMRA (CD45RA+CCR7-) CD8+ T cells had an improved CBR (76% vs 25%, p=0.005), an improved PFS (HR=0.35, CI95, 0.13-0.95, p=0.013) and an improved OS (HR=0.19, CI95, 0.07-0.53, p=0.001). Multivariate analysis with classical CC prognostic factors confirmed the OS benefit of our biomarker (HR=0.15, CI95: 0.05-0.47, <0.001).
- Open Access
- 4 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
A CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trial
Immune checkpoint inhibitors (ICIs) have transformed treatment for non-small cell lung cancer (NSCLC), but resistance to these therapies is common. We report here results from a phase I trial combining intratumoral injection of a CCL21-expressing dendritic cell (CCL21-DC) vaccine with pembrolizumab in patients with advanced non-small cell lung cancer (ClinicalTrials.gov identifier: NCT03546361). The primary objectives were to determine the maximum administered dose (MAD) in the dose escalation phase and the objective response rate (ORR) in the dose expansion. Eleven patients were enrolled in the dose escalation cohort, and 12 patients were treated in the dose expansion cohort at the MAD of 3 ×10 7 cells/injection. The trial did not meet its primary endpoint for ORR as no objective responses were observed, though 36.8% of patients achieved a best response of stable disease. The combination therapy was well tolerated. Post-hoc analyses of longitudinal biopsies revealed that the therapy increased tumor infiltration by CD4+ T cells and novel T cell clones. Disease stability was associated with increased T cell receptor diversity and greater expansion of novel clones following therapy. However, many novel clones failed to persist over time, and immunosuppressive myeloid signaling signatures were identified across time points. Our findings overall demonstrated that CCL21-DC vaccination combined with pembrolizumab can promote T cell infiltration, but this did not translate into meaningful clinical efficacy, potentially due to limited tumor specificity of the T cell response and an inability to fully reprogram the tumor microenvironment.
- 4 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessA CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trial
Immune checkpoint inhibitors (ICIs) have transformed treatment for non-small cell lung cancer (NSCLC), but resistance to these therapies is common. We report here results from a phase I trial combining intratumoral injection of a CCL21-expressing dendritic cell (CCL21-DC) vaccine with pembrolizumab in patients with advanced non-small cell lung cancer (ClinicalTrials.gov identifier: NCT03546361). The primary objectives were to determine the maximum administered dose (MAD) in the dose escalation phase and the objective response rate (ORR) in the dose expansion. Eleven patients were enrolled in the dose escalation cohort, and 12 patients were treated in the dose expansion cohort at the MAD of 3 ×10 7 cells/injection. The trial did not meet its primary endpoint for ORR as no objective responses were observed, though 36.8% of patients achieved a best response of stable disease. The combination therapy was well tolerated. Post-hoc analyses of longitudinal biopsies revealed that the therapy increased tumor infiltration by CD4+ T cells and novel T cell clones. Disease stability was associated with increased T cell receptor diversity and greater expansion of novel clones following therapy. However, many novel clones failed to persist over time, and immunosuppressive myeloid signaling signatures were identified across time points. Our findings overall demonstrated that CCL21-DC vaccination combined with pembrolizumab can promote T cell infiltration, but this did not translate into meaningful clinical efficacy, potentially due to limited tumor specificity of the T cell response and an inability to fully reprogram the tumor microenvironment.
- Open Access
- 25 June 2026
- Published by Taylor & Francis in Future Oncology
- Vol. 22 (15) , 1-16
Evaluating datopotamab deruxtecan (Dato-DXd) as a novel treatment option for EGFR-mutated non-small cell lung cancer
Datopotamab deruxtecan (Dato-DXd) is a TROP2-directed antibody-drug conjugate (ADC) that has received accelerated approval in the US for adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) after progression on EGFR-directed therapy and platinum chemotherapy. In pooled analyses from TROPION-Lung01 and TROPION-Lung05, Dato-DXd achieved an objective response rate of ~45% and a median duration of response of 6.5 months, which compares favorably with historical outcomes with docetaxel. Dato-DXd is being evaluated in combination with osimertinib in the first-line and post-osimertinib settings, following encouraging activity in the phase II ORCHARD platform trial evaluating therapeutic strategies for EGFR-TKI-resistant disease. Importantly, Dato-DXd demonstrates a favorable safety profile and has lower rates of grade ≥3 adverse events and less hematologic toxicity than docetaxel. Adverse events of special interest include mucositis, interstitial lung disease, and ocular surface events. While these toxicities are generally manageable, they require prophylaxis, monitoring, and early intervention. Current research aims to elucidate the mechanisms underlying these toxicities and to identify modifiable risk factors to further improve tolerability. The biological mechanisms contributing to the differential efficacy of Dato-DXd are also under investigation and may further inform its clinical role.Expert opinion: Determining how best to integrate Dato-DXd within existing treatment sequences has the potential to meaningfully address persistent unmet needs in EGFR-mutated NSCLC.
- 25 June 2026
- Published by Taylor & Francis in Future Oncology
- Vol. 22 (15) , 1-16
Open AccessEvaluating datopotamab deruxtecan (Dato-DXd) as a novel treatment option for EGFR-mutated non-small cell lung cancer
Datopotamab deruxtecan (Dato-DXd) is a TROP2-directed antibody-drug conjugate (ADC) that has received accelerated approval in the US for adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) after progression on EGFR-directed therapy and platinum chemotherapy. In pooled analyses from TROPION-Lung01 and TROPION-Lung05, Dato-DXd achieved an objective response rate of ~45% and a median duration of response of 6.5 months, which compares favorably with historical outcomes with docetaxel. Dato-DXd is being evaluated in combination with osimertinib in the first-line and post-osimertinib settings, following encouraging activity in the phase II ORCHARD platform trial evaluating therapeutic strategies for EGFR-TKI-resistant disease. Importantly, Dato-DXd demonstrates a favorable safety profile and has lower rates of grade ≥3 adverse events and less hematologic toxicity than docetaxel. Adverse events of special interest include mucositis, interstitial lung disease, and ocular surface events. While these toxicities are generally manageable, they require prophylaxis, monitoring, and early intervention. Current research aims to elucidate the mechanisms underlying these toxicities and to identify modifiable risk factors to further improve tolerability. The biological mechanisms contributing to the differential efficacy of Dato-DXd are also under investigation and may further inform its clinical role.Expert opinion: Determining how best to integrate Dato-DXd within existing treatment sequences has the potential to meaningfully address persistent unmet needs in EGFR-mutated NSCLC.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma
Figure S4. Quantification of CD31 in xenografts treated with Vehicle, TAK228, pazopanib, EIPA or combinations.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma
Figure S4. Quantification of CD31 in xenografts treated with Vehicle, TAK228, pazopanib, EIPA or combinations.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma
Figure S5. PDXs have different extent of CD31 positive staining.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma
Figure S5. PDXs have different extent of CD31 positive staining.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Data from Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma
The capacity of cancer cells to rewire their cellular metabolism in response to therapeutic pressure confers resistance to treatments targeting key metabolic pathways, which represents a significant challenge in personalized cancer therapy for lung tumors. In this study, we investigated the mechanisms of resistance to the small-molecule mTOR inhibitor TAK228 across lung squamous cell carcinoma (LUSC) models, including cell lines, xenografts, and patient-derived xenografts (PDX). LUSC cells adapted to mTOR inhibition by engaging macropinocytosis, a form of endocytosis that facilitates enhanced uptake of extracellular nutrients, thereby increasing amino acid availability. Coinhibition of both mTOR and macropinocytosis using small-molecule inhibitors effectively reduced tumor growth. Additionally, angiogenesis limited the efficacy of inhibition of mTOR and macropinocytosis by ensuring a sufficient nutrient supply. Notably, inhibiting angiogenesis in combination with inhibitors of mTOR and macropinocytosis reduced tumor growth in xenografts and PDXs. Moreover, prolonged treatment of LUSC PDXs with TAK228 and the glutaminase inhibitor CB-839 led to upregulation of vascularization, which coincided with a rebound in tumor growth despite continued therapeutic administration. These findings highlight adaptive resistance mechanisms to small-molecule inhibitors that target key metabolic pathways, lending insights into potential future clinical strategies for the treatment of LUSC.Significance:Macropinocytosis and angiogenesis are adaptive mechanisms that support nutrient uptake and availability to drive resistance to metabolic therapies, providing a promising future therapeutic strategy to overcome metabolic flexibility of lung cancer.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma
The capacity of cancer cells to rewire their cellular metabolism in response to therapeutic pressure confers resistance to treatments targeting key metabolic pathways, which represents a significant challenge in personalized cancer therapy for lung tumors. In this study, we investigated the mechanisms of resistance to the small-molecule mTOR inhibitor TAK228 across lung squamous cell carcinoma (LUSC) models, including cell lines, xenografts, and patient-derived xenografts (PDX). LUSC cells adapted to mTOR inhibition by engaging macropinocytosis, a form of endocytosis that facilitates enhanced uptake of extracellular nutrients, thereby increasing amino acid availability. Coinhibition of both mTOR and macropinocytosis using small-molecule inhibitors effectively reduced tumor growth. Additionally, angiogenesis limited the efficacy of inhibition of mTOR and macropinocytosis by ensuring a sufficient nutrient supply. Notably, inhibiting angiogenesis in combination with inhibitors of mTOR and macropinocytosis reduced tumor growth in xenografts and PDXs. Moreover, prolonged treatment of LUSC PDXs with TAK228 and the glutaminase inhibitor CB-839 led to upregulation of vascularization, which coincided with a rebound in tumor growth despite continued therapeutic administration. These findings highlight adaptive resistance mechanisms to small-molecule inhibitors that target key metabolic pathways, lending insights into potential future clinical strategies for the treatment of LUSC.Significance:Macropinocytosis and angiogenesis are adaptive mechanisms that support nutrient uptake and availability to drive resistance to metabolic therapies, providing a promising future therapeutic strategy to overcome metabolic flexibility of lung cancer.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma
Figure S3. Quantification of CD31 in xenografts treated with Vehicle or TAK228.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma
Figure S3. Quantification of CD31 in xenografts treated with Vehicle or TAK228.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma
Figure S2. TAK228 treatment induces accumulation of Lysotracker in LUSC cell lines.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma
Figure S2. TAK228 treatment induces accumulation of Lysotracker in LUSC cell lines.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma
Figure S1. Treatment with TAK228 does not increase CD31 density in H1703 and H2170 xenografts.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma
Figure S1. Treatment with TAK228 does not increase CD31 density in H1703 and H2170 xenografts.
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (2) , 306-313
Adequacy of Immune Checkpoint Inhibitor–Associated Thyroid Function Monitoring After Therapy
PURPOSE: Immune checkpoint inhibitor (ICI)-induced thyroid dysfunction is a common endocrine immune-related adverse event. Although rates during therapy are well documented, data on post-treatment thyroid dysfunction are limited. We hypothesized that post-ICI thyroid dysfunction is under-recognized because of inadequate surveillance. METHODS: A retrospective analysis of 3,626 patients treated with ICIs for various malignancies within a single health system was conducted. Clinically acted-upon thyroid dysfunction (diagnosis or thyroid-directed medication) was evaluated before, during, and after ICI therapy, alongside rates of thyroid laboratory surveillance. RESULTS: Clinically acted-upon thyroid dysfunction occurred in 8.1% (294/3,626) during treatment and 4.4% (159/3,626) after treatment. Among the 1,170 patients with post-ICI thyroid laboratory results and no prior dysfunction, 11.6% (136/1,170) developed post-ICI thyroid dysfunction. However, 48.6%% (1,764/3,626) had no post-ICI thyroid laboratory results. Thirty percent of patients with abnormal thyroid stimulating hormone (TSH) values and no clinically acted-upon thyroid dysfunction before therapy discontinuation subsequently developed clinically acted-upon thyroid dysfunction, and the rate of post-ICI clinically acted-upon thyroid dysfunction was higher in patients who received 9 or less months of ICI therapy. CONCLUSION: Post-ICI thyroid dysfunction is frequent, with 11.6% of monitored patients being affected, and patients with abnormal TSH before ICI discontinuation and those who received treatment for 9 months or less may benefit from more stringent post-ICI surveillance.
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (2) , 306-313
Adequacy of Immune Checkpoint Inhibitor–Associated Thyroid Function Monitoring After Therapy
PURPOSE: Immune checkpoint inhibitor (ICI)-induced thyroid dysfunction is a common endocrine immune-related adverse event. Although rates during therapy are well documented, data on post-treatment thyroid dysfunction are limited. We hypothesized that post-ICI thyroid dysfunction is under-recognized because of inadequate surveillance. METHODS: A retrospective analysis of 3,626 patients treated with ICIs for various malignancies within a single health system was conducted. Clinically acted-upon thyroid dysfunction (diagnosis or thyroid-directed medication) was evaluated before, during, and after ICI therapy, alongside rates of thyroid laboratory surveillance. RESULTS: Clinically acted-upon thyroid dysfunction occurred in 8.1% (294/3,626) during treatment and 4.4% (159/3,626) after treatment. Among the 1,170 patients with post-ICI thyroid laboratory results and no prior dysfunction, 11.6% (136/1,170) developed post-ICI thyroid dysfunction. However, 48.6%% (1,764/3,626) had no post-ICI thyroid laboratory results. Thirty percent of patients with abnormal thyroid stimulating hormone (TSH) values and no clinically acted-upon thyroid dysfunction before therapy discontinuation subsequently developed clinically acted-upon thyroid dysfunction, and the rate of post-ICI clinically acted-upon thyroid dysfunction was higher in patients who received 9 or less months of ICI therapy. CONCLUSION: Post-ICI thyroid dysfunction is frequent, with 11.6% of monitored patients being affected, and patients with abnormal TSH before ICI discontinuation and those who received treatment for 9 months or less may benefit from more stringent post-ICI surveillance.